HIGHLIGHTS FROM ELCC 2025
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Promising activity reported with second-line TKIs in oncogene-addicted advanced NSCLC
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
Is it time for pathologists to take a more active role in lung cancer?
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
SARCOMA & RARE CANCERS
Two novel approaches provide new insights into prognostic markers for rare adrenal cancers
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Long-term nirogacestat shows sustained benefits in desmoid tumours
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
TARGETED THERAPIES
Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
First-line combination of an antibody–drug conjugate plus immunotherapy shows promise in non-small cell lung cancer
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
Can AI and liquid biopsies take precision oncology to the next level?
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries
OPINIONS
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
OPINIONS
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank